Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics,
and consumer health products, today announced that Dr. Donald E. Morel
will be added to its Board of Directors, effective the next time the
Board convenes, increasing the size of the Board to ten members.
Dr. Morel retired in June 2015 as Chairman of West Pharmaceutical
Services, Inc. (“West”), a leading manufacturer of packaging components
and delivery systems for injectable drugs and healthcare products, a
position he had held since March 2003. He also served as West’s Chief
Executive Officer from April 2002 until April 2015 and as its President
from April 2002 until June 2005.
Currently, Dr. Morel serves as Chairman of the Board of Directors of the
American Oncologic Hospital of the Fox Chase Cancer Center. He also
serves as Chairman of the Board of Trustees of the Franklin Institute
and is a Trustee of Lafayette College. Additionally, Dr. Morel has been
a Director of Integra Life Sciences Holdings Corporation since August
2013. Prior to that, he served as a Director of Kensey Nash Corporation
from 2010 until 2012.
John Chiminski, President and Chief Executive Officer of Catalent, Inc.,
said, “We are extremely excited to be able to strengthen our Board with
yet another pharmaceutical services veteran. Don has a proven track
record of executive leadership and strategic vision, having grown West
into a universally recognized name in the market. We look forward to his
many insightful contributions toward enhancing Catalent’s market
leadership.”
“Having seen first hand Catalent’s significant value proposition, I am
excited by the opportunity to leverage my years of industry experience,
alongside an already impressive Board, to help Catalent capitalize on
its many opportunities for growth,” commented Dr. Morel.
Dr. Morel obtained a Master of Science degree and a Ph.D. in Materials
Science from Cornell University and a Bachelor of Science degree in
Engineering from Lafayette College.
About Catalent, Inc.
Catalent, Inc. (NYSE:CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs more than 8,700
people, including over 1,000 scientists, at 31 facilities across 5
continents and in fiscal 2015 generated more than $1.8 billion in annual
revenue. Catalent is headquartered in Somerset, N.J. For more
information, please visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
Investor Contact:
Catalent, Inc.
Thomas Castellano, 732-537-6325
investors@catalent.com